Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
22nd China Golden Horse Awards Ceremony held in Shenzhen
Bautista Agut earns 399th tour
Did Dwayne Johnson say he regretted supporting Biden in 2020? — Radio Free Asia
It's no wonder parents are taking their children on holiday during term time! Sky
Missing Kansas women confirmed dead, kids safe, 4 charged with kidnapping and murder
Savoring dream life in Tibet with a coffee van
China, Albania sign MOU on tourism cooperation
Candice Swanepoel stuns in a form
1 killed, 11 more people hurt in shooting in New Orleans
Sophie Morgan suddenly quits ITV show Loose Women as she reveals plans for emigration
The 39th Harbin International Ice and Snow Festival is around the corner